IBRX stock news · ImmunityBio
Get alerts for IBRX
Follow ImmunityBio (IBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IBRXImmunityBio shared good early results for its CD19 CAR-NK therapy, showing it works for treating Waldenstrom's macroglobulinemia.
Good for IBRXImmunityBio said its experimental CD19 CAR-NK treatment cleared symptoms in 2 patients, with 1 still in remission after 6 months. The early report is encouraging for its cancer program.
ImmunityBio's research reveals that its bladder cancer treatment works well over a long time.
Good for IBRXImmunityBio reported lasting bladder-cancer responses with ANKTIVA plus BCG. The study strengthens the treatment's case, despite weaker short-term trading signals.
ImmunityBio's stock went up on Thursday after news about its cancer treatment approval.
Good for IBRXFDA expanded ANKTIVA’s use to papillary-only bladder cancer, the largest patient group in this disease. ImmunityBio can reach more patients, though approval relies on results from another group.
ImmunityBio, Inc. shares new information in a filing with the SEC.
NeutralImmunityBio filed an SEC report that lists an attached press release, but the report does not include its contents. It gives no clear reason to change the outlook for the company.
ImmunityBio's stock is up on Wednesday after the FDA approved its drug for more uses.
Good for IBRXThe FDA expanded ImmunityBio’s Anktiva approval to cover another bladder cancer group. This broadens the potential patient pool, though the decision relies on results from CIS patients.
ImmunityBio's stock shot up to about $10.50 after rising from $8.25 just two days ago.
NeutralImmunityBio shares climbed, but the story gives no confirmed business reason for the move. It does not change the company’s outlook.